Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-25 @ 4:06 AM
Ignite Modification Date:
2025-12-26 @ 3:02 AM
NCT ID:
NCT03593902
Group ID:
EG000
Title:
Hematopoietic Stem Cell Transplantation
Description:
Hematopoietic Stem Cell Therapy will be performed as follows: Autologous stem cells will be infused after conditioning with rituximab, fludarabine, cyclophosphamide, Mesna, rATG (rabbit), and methylprednisolone. Granulocyte-colony stimulating factor (G-CSF) and intravenous immunoglobulin (IVIg) will be administered post-transplant.
Rituximab: Monoclonal antibody therapy used to treat certain autoimmune diseases and types of cancer
Fludarabine: A chemotherapy medication commonly used in the treatment of leukemia \& lymphoma
Cyclophosphamide: A medication used as chemotherapy and to suppress the immune system
Mesna: A medication used in those taking cyclophosphamide or ifosfamide to decrease the risk of bleeding from the bladder
rATG: A rabbit polyclonal antibody to lymphocytes
Methylprednisolone: A corticosteroid medication used to suppress the immune system and decrease inflammation
G-CSF: A glycoprotein that stimulates the bone marrow to produce granulocytes and
Deaths Number Affected:
0
Deaths Number At Risk:
None
Serious Number Affected:
0
Serious Number At Risk:
9
Other Number Affected:
0
Other Number At Risk:
9
Study:
NCT03593902
Results Section:
NCT03593902
Adverse Events Module:
NCT03593902